Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus crispatus LBV88
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus crispatus LBV88 is a specific probiotic bacterial strain belonging to the species Lactobacillus crispatus, which is a dominant member of the healthy human vaginal microbiota. As a live biotherapeutic, LBV88 is utilized to restore vaginal microbial balance (eubiosis) by producing lactic acid to maintain an acidic pH and generating hydrogen peroxide to inhibit the overgrowth of pathogenic organisms. It is primarily developed and marketed by Institut AllergoSan as part of multi-strain probiotic formulations like OMNi-BiOTiC FLORA plus+. Clinical investigations have focused on its role in improving reproductive health outcomes, including the management of vaginal dysbiosis in women with infertility and the prevention of complications such as gestational diabetes mellitus during pregnancy.
- Other names
- Lactobacillus crispatus LBV88L. crispatus LBV88
Beyond the preview
Go deeper on lactobacillus crispatus LBV88.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus crispatus LBV88.